Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved...
Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved...
Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved...
FORT MYERS, Fla. and FREMONT, Calif., April 29, 2025 /PRNewswire/ -- NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology diagnostic...
New York, NY, April 29, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on...
Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignanciesVANCOUVER, British Columbia, April 29, 2025...
Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignanciesVANCOUVER, British Columbia, April 29, 2025...
Oslo, April 29, 2025: Zelluna ASA held its annual general meeting today April 29, 2025. All the matters on the...
Oslo, April 29, 2025: Zelluna ASA held its annual general meeting today April 29, 2025. All the matters on the...
Collaboration aims to use FYR’s AI-enabled EV-Omics (EVO) platform to produce dynamic, real-time insights into Parkinson’s diseaseMISSOULA, Mont., April 29,...
Collaboration aims to use FYR’s AI-enabled EV-Omics (EVO) platform to produce dynamic, real-time insights into Parkinson’s diseaseMISSOULA, Mont., April 29,...
BOSTON, April 28, 2025 /PRNewswire/ -- Volta Labs, Inc. today announced the launch of the Volta Access Program, a new...
BOSTON and ROLLE, Switzerland, April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader...
Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA®...
Fragmentomics pioneer showcases DELFI-TF treatment monitoring solution alongside early detection capabilities at a premier oncology research event BALTIMORE and PALO...
Fragmentomics pioneer showcases DELFI-TF treatment monitoring solution alongside early detection capabilities at a premier oncology research event BALTIMORE and PALO...
Novel analytical framework establishes a clinically meaningful performance assessment of blood-based early detection tests Innovative methodology enhances cancer signal detection,...
Novel analytical framework establishes a clinically meaningful performance assessment of blood-based early detection tests Innovative methodology enhances cancer signal detection,...
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour ...
All patients achieved 20/30 or better best corrected distance visual acuity (BCDVA)Significant IOP reduction at 18 months was also demonstrated...